Targeted Therapeutics for Inflammatory Disease Jefferies Healthcare Conference
|
|
- Cornelia Haynes
- 5 years ago
- Views:
Transcription
1 Targeted Therapeutics for Inflammatory Disease 2016 Jefferies Healthcare Conference
2 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations, are forward looking statements. In some cases, you can identify forward-looking statements by terminology such as believe, will, may, estimate, continue, anticipate, intend, should, plan, might, approximately, expect, predict, could, potentially or the negative of these terms or other similar expressions. Forward looking statements appear in a number of places throughout this presentation and the accompanying oral commentary and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for AQX-1125 and our future product candidates, our intellectual property position, the degree of clinical utility of AQX-1125 and our future product candidates, particularly in specific patient populations, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption Risk Factors set forth in our Year End Report on Form 10-K for the year-end ended March 31, 2016, which we filed with the Securities and Exchange Commission ( SEC ) on April 10, 2016 and other reports and filings we will make with the SEC from time to time. Forward-looking statements represent our management s beliefs and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. 2
3 Corporate Highlights First in class drug targeting novel enzyme (SHIP1) with broad antiinflammatory potential Positive Phase 2 results in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Well capitalized to advance Phase 3 program Competitive advantage in large, underserved market suitable for independent commercialization in the US, partner RoW 3
4 SHIP1 - Nature s Path to Suppress Inflammation Potential Next-Gen Anti-Inflammatory Drugs ü Restricted expression to hematopoietic derived cells limits off tissue toxicity PI-4,5-P 2 PI3K All cells PIP 3 SHIP1 Immune cells PI-3,4-P 2 ü Plays key role in regulating cell migration and activation PTEN All cells SHIP1 Activators ü SHIP1 activators redirect signalling, not block it Cancer Cell growth and survival Inflammation Cell activation and function ü Non-catalytic binding site imparts target selectivity and limits off target toxicity 4
5 A Novel First in Class Anti-Inflammatory Therapy AQX-1125, a SHIP1 activator: Broad anti-inflammatory potential Favourable ADME: Once daily oral administration T½ 21hrs Dose proportional PK, No food effect High bioavailability; Not metabolized ~60/40 Liver/Renal elimination as unchanged parent Well tolerated in 7 completed clinical trials >360 subjects dosed 5
6 Lead Indication: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): A Severe and Debilitating Inflammatory Disease Chronic erosion of the bladder lining, exposing the bladder wall to irritation and inflammation Associated with significant pain and urinary symptoms with a dramatic impact on quality of life One of the most challenging conditions known to the urology community 1) NIH-NIDDK Publica1on No Sept 2011; 2) Bogart et al Urology (3):576-80; 3) Hepner et al Urology, 80(2)
7 Unmet Medical Need Estimated prevalence in the US of ~5-12M ~ M women 1, ~ M men 2 Relatively low diagnosis rate (~8%) 3 In current practice, 1:10 male to female ratio typically observed Expected to increase with improved disease definition and the emergence of new treatment options 3 Limited treatment options No new FDA approved oral treatment in 20 years 4 Other treatments are invasive (including bladder instillation) 4 1) Berry. J Urol. 2011;186:540; 2) Suskind. J Urol. 2013;189:141; 3) ClearView Analysis: Physician Interviews; 4) 2014 AUA Treatment Guidelines 7
8 IC/BPS Heightened Awareness 8
9 Phase 2 LEADERSHIP Trial: A Comprehensive IC/BPS Trial Population and Entry Demographics: 69 female patients across US and Canadian sites with moderate to severe IC/BPS symptoms: Mean pain > 5/10 Mean BPIC/SS and O Leary Sant ICSI/PI symptom scores 19 or 8 respectively On background medication (excluding opiates) Primary Endpoint: - Reduction of average daily pain at 6 weeks with once daily AQX-1125 vs. placebo Pre-specified Secondary Endpoints: - Maximum daily pain based on an 11-point NRS recorded by ediary - Average and maximum daily pain score measured by 11-point NRS recorded at clinic - Multiple urological and QoL symptom assessments (O Leary-Sant ICSI/PI, BPIC-SS) - Voiding frequency over a 24 hour period Safety, Pharmacokinetics 9
10 LEADERSHIP: Greater Average Daily Pain Reduction Over 6 Weeks (ediary) # Average Daily Pain (11-Point NRS, ediary) # Primary Endpoint Average Daily Pain at 6 weeks did not meet sta:s:cal significance 10
11 LEADERSHIP: Significantly Reduced Maximum Daily Pain Over 6 Weeks (ediary) Maximum Daily Pain (11-point NRS, ediary) 11
12 LEADERSHIP: Summary of Key Primary and Secondary Endpoints at 6 Weeks Endpoint (Change from Baseline at 6 weeks) Placebo (n=32) (mean change from baseline) AQX-1125 (n=37) (mean change from baseline) Difference in LSM AQX Placebo p value PAIN (11-point NRS) Average Daily Pain (e-diary) Maximum Daily Pain (e-diary) * Average Daily Pain (clinic) * Maximum Daily Pain (clinic) * SYMPTOM QUESTIONNAIRES O Leary-Sant IC Symptom Index (ICSI) * O Leary-Sant IC Problem Index (ICPI) * Combined O Leary-Sant ICSI/ICPI * BPIC-SS * VOIDING FREQUENCY Number of Voids/24h (e-diary) * 1 Primary endpoint for 301 trial *StaTsTcally Significant 12
13 AQX-1125: Bladder Exposure Through Blood & Urine Concentration (ng/ml) LEADERSHIP, 4 Weeks, Plasma Phase 2a LPS Challenge, 7 Days, Plasma LEADERSHIP, 6 Weeks, Plasma LEADERSHIP, 4 Weeks, Urine LEADERSHIP, 6 Weeks, Urine 13
14 Overall Safety Summary of Oral AQX-1125 (200mg) Across Ph 2 Trials with at least 6 Weeks Daily Dosing LEADERSHIP (AQX ) IC/BPS pts (6-week dosing) COMBINED SAFETY DATA Ph2 Trials with 200mg daily dosing for 6 or 12 weeks (LEADERSHIP, KINSHIP, FLAGSHIP) Placebo N=32 n* (%) AQX-1125 N=37 n* (%) Placebo N=260 n* (%) AQX-1125 N=263 n* (%) TEAE 25 (78) 22 (60) 143 (55) 148 (56) GI Disorders 1 11 (34) 11 (30) 42 (16) 54 (21) Eye Disorders 2 3 (9) 2 (5) 25 (10) 18 (7) SAEs 0 (0) 0 (0) 18 (7) 12 (5) Deaths 0 (0) 0 (0) 1 (0.4) 1 (0.4) TEAEs Leading to DisconTnuaTon 1 (3) 2 (5) 12 (5) 15 (6) TEAEs shown are those reported from the start of dosing through to the end of the 28-day follow-up *n = number of subjects with 1 event. Subjects counted once per SOC, PT and Treatment group. 1. GI disorders are specifically included as adverse events of interest, due to their increased incidence rela^ve to other events in earlier Phase 1 clinical studies (at greater than two-fold higher doses of mg; none of which were serious). 2. Eye disorders are specifically included as adverse events of interest since there were non-clinical ophthalmologic findings. 14
15 IC/BPS Commercial Opportunity 15
16 Untapped Market with Growth Potential 12 M Up to 12 M 5 M 4 M 2.1 M Effective therapy has potential to unlock market Men Women 3 M 2 M 1 M 3.3 M Elmiron FY sales $279 M M US Prevalence Diagnosed Treated 16
17 Specialist Driven Prescribing Suitable for Independent Commercialization in the US, Partner RoW Prescribing Physician Elmiron Scripts % of Scripts TOTAL 495, % Urologists 239,858 48% Obstetrics/Gynecologists 97,882 20% Family Practice 33,491 7% Osteopathic Medicine 28,450 6% Nurse Practitioner 26,889 5% Internal Medicine 26,710 5% Physician Assistant 14,737 3% Specialty Unspecified 10,118 2% Source: IMS Health Report,
18 IC/BPS Phase 3 Trial Timelines Ini^a^on (Q3/16) 12 Weeks Dosing with one of Two Doses of AQX-1125 or Placebo Top Line Data (Q4/17) Single Dose AQX-1125 for Safety Database 301 Treatment Phase 40 wk Open Label Extensions 302 Treatment Phase 14 wk OLE 12 Weeks Dosing with Single Dose of AQX-1125 or placebo 18
19 Focused Strategy with Broader Opportunities Building on the Success of LEADERSHIP with AQX-1125 Potential Development with AQX-1125 Urinary Tract IC/BPS Glomerulonephritis Prostatitis Gastrointestinal Ulcerative Colitis Crohn's Disease Eosinophilic Esophagitis 19
20 Prospective Near-Term Milestones Near-term data, expanded market opportunities and pipeline advancement Abstracts at EAU, AUA and CUA Initiate Mouse Carcinogenicity Study Publication of Leadership Data Initiation of IC/BPS Pivotal Trial Tablet Manufacturing for Leadership 301 Initiate ADME Trial Initiate Rat Carcinogenicity Study Safety & Other Required Phase 1 Trials ( 1 Renal, 1 Hepatic and TQT) Report ADME results IC/BPS Top-Line Data (Q4) Potential New AQX-1125 Indication Ini:a:on and Timing Capital Dependent 20
21 Financial & Stock Information ~ $107.3M cash as at March 31 st, 2016 ~ $21.3M operating expenses in M Shares Outstanding (~18.1M fully diluted) Cash to fund first Phase 3 trial and supporting activities NASDAQ : AQXP 21
22
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationTargeted Therapeutics for Inflammatory Disease. June 2017
Targeted Therapeutics for Inflammatory Disease June 2017 1 Forward Looking Statements/ Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve
More informationTargeted Therapeutics for Inflammatory Disease. June 2018
Targeted Therapeutics for Inflammatory Disease June 2018 1 Forward Looking Statements/ Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Jefferies Global Healthcare Conference June 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationTargeted Therapeutics for Inflammatory Disease. February 2018
Targeted Therapeutics for Inflammatory Disease February 2018 1 Forward Looking Statements/ Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve
More informationTargeted Therapeutics for Inflammatory Disease. Investor Presentation April 2014
Targeted Therapeutics for Inflammatory Disease Investor Presentation April 2014 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationKeyzilen TM Program Update
Keyzilen TM Program Update October 11, 2016 Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties.
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationFebruary 20, 2019 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES
February 20, 209 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES Forward-Looking Statements This presentation contains certain forward-looking statements that are made pursuant
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationTransforming Treatment for Migraine. 16 th Annual Needham Healthcare Conference April 4, 2017
Transforming Treatment for Migraine 16 th Annual Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and the accompanying commentary contain certain forward-looking
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life
Breathtaking science Developing respiratory drugs to improve health and quality of life June 2017 Forward-Looking Statements This presentation contains forward looking statements that are based on the
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationParadigm for Migraine Patients
June Transforming 14, 2018 the Prevention Treatment Paradigm for Migraine Patients January 2019 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationLJPC-401 Phase 1 Results and Development Update. September 7, 2016
LJPC-401 Phase 1 Results and Development Update September 7, 2016 Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationMarket Potential for MDX Alcobra Investor Breakfast July 15, 2014
Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases,
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationGW Pharmaceuticals plc. Investor Presentation August 2014
GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations
More informationPress Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D
Press Release RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled
More informationFirst self-administered antibody therapy for HIV in late-stage clinical trials. CytoDyn Annual Meeting of Stockholders August 24, 2017
First self-administered antibody therapy for HIV in late-stage clinical trials CytoDyn Annual Meeting of Stockholders August 24, 2017 (OTCQB: CYDY) www.cytodyn.com Forward-Looking Statements This presentation
More informationCreating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016
Creating a Leading Global HBV Therapeutics Company ARB-1467 Update Call December 12, 2016 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationProsensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, Hans Schikan, CEO
Prosensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, 2014 Hans Schikan, CEO Forward-Looking Statements This presentation may contain statements that constitute forward-looking
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationNew SEL-212 Phase 2 Data Presented at EULAR. June 15, 2018
New SEL-1 Phase Data Presented at EULAR June 15, 1 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ( the company
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationHTX-011 Postoperative Pain Program Topline Results From Phase 3. March 19, 2018
HTX-011 Postoperative Pain Program Topline Results From Phase 3 March 19, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationBuilding a Franchise in HDV. Pegylated Interferon Lambda-1a
Building a Franchise in HDV Sarasar (lonafarnib) Pegylated Interferon Lambda-1a Forward-Looking Statements This presentation and the oral commentary contain forward-looking statements that involve substantial
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCorporate Presentation January 2013
NASDAQ: ANTH Corporate Presentation January 2013 1 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationUtrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018
Utrophin Modulation: A Universal Treatment Approach to DMD April 2018 Legal Disclaimer Statements in this presentation, other than statements of historical fact, constitute forward-looking statements within
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationDavid Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019
David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on
More informationpsivida Transforms into Commercial Stage Specialty BioPharmaceutical Company AAO October 25, 2018 NASDAQ: EYPT
psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company OIS @ AAO October 25, 2018 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
More informationNASDAQ: WINT. April 2016
NASDAQ: WINT April 2016 Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company s business strategy, outlook, objectives,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More information